French Observatory of Rare Malignant Tumors of the Ovary
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01304043 |
Recruitment Status
:
Completed
First Posted
: February 25, 2011
Last Update Posted
: April 20, 2012
|
Sponsor:
ARCAGY/ GINECO GROUP
Information provided by (Responsible Party):
ARCAGY/ GINECO GROUP
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | September 9, 2005 | |||
First Posted Date | February 25, 2011 | |||
Last Update Posted Date | April 20, 2012 | |||
Study Start Date | January 2002 | |||
Primary Completion Date | Not Provided | |||
Current Primary Outcome Measures | Not Provided | |||
Original Primary Outcome Measures | Not Provided | |||
Change History | Complete list of historical versions of study NCT01304043 on ClinicalTrials.gov Archive Site | |||
Current Secondary Outcome Measures | Not Provided | |||
Original Secondary Outcome Measures | Not Provided | |||
Current Other Outcome Measures | Not Provided | |||
Original Other Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | French Observatory of Rare Malignant Tumors of the Ovary | |||
Official Title | Observatoire Francophone Des Tumeurs Malignes Rares de l'Ovaire : Protocole de Prise en Charge Chez l'Adulte (Tumeurs Germinales et Des Cordons Sexuels) | |||
Brief Summary | To take charge of the treatment in rare adult ovarian tumors with an homogenous manner (germinal and sexual cords tumors), at different stages of the disease. | |||
Detailed Description |
|
|||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | female with rare ovarian cancer | |||
Condition | Ovarian Tumors | |||
Intervention | Drug: chemotherapies protocols
Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV |
|||
Study Groups/Cohorts | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment |
204 | |||
Original Estimated Enrollment |
150 | |||
Actual Study Completion Date | June 2011 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
|||
Sex/Gender |
|
|||
Ages | 18 Years and older (Adult, Senior) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | France | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT01304043 | |||
Other Study ID Numbers | TMRO | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | ARCAGY/ GINECO GROUP | |||
Study Sponsor | ARCAGY/ GINECO GROUP | |||
Collaborators | Not Provided | |||
Investigators |
|
|||
PRS Account | ARCAGY/ GINECO GROUP | |||
Verification Date | April 2012 |